Published in Gastroenterology on January 05, 2007
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant (2010) 1.67
Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol (2008) 0.94
New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis (2016) 0.91
Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol (2013) 0.90
Liver transplantation: yesterday, today and tomorrow. World J Gastroenterol (2008) 0.88
The management of patients awaiting liver transplantation. Nat Rev Gastroenterol Hepatol (2009) 0.86
Utilization of expanded criteria donors in liver transplantation. Int J Organ Transplant Med (2013) 0.83
Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl (2013) 0.83
Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation. BMC Gastroenterol (2010) 0.82
Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am (2010) 0.82
Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol (2011) 0.81
Changing pattern of donor selection criteria in deceased donor liver transplant: a review of literature. J Clin Exp Hepatol (2013) 0.80
Safe and cost-effective control of post-transplantation recurrence of hepatitis B. Hepatol Res (2014) 0.79
Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation. Gastroenterol Hepatol (N Y) (2014) 0.79
The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation. Langenbecks Arch Surg (2011) 0.79
Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome. World J Gastroenterol (2014) 0.79
Management of chronic hepatitis B in severe liver disease. World J Gastroenterol (2014) 0.78
Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2009) 0.78
Management of viral hepatitis in liver transplant recipients. Clin Mol Hepatol (2014) 0.77
Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. Int J Mol Sci (2015) 0.76
Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Mon (2012) 0.76
Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. World J Gastroenterol (2015) 0.76
Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam (2014) 0.76
Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2015) 0.76
Hepatitis B immunoglobulin prophylaxis after liver transplantation: experience in a tertiary transplant centre. J Clin Exp Hepatol (2014) 0.76
Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int (2011) 0.76
Hepatitis: viral load predicts HBV recurrence after liver transplant. Nat Rev Gastroenterol Hepatol (2010) 0.75
Simple nucleos(t)ides as HBV prophylaxis regime of post-liver transplantation: Six-year followed up. World J Hepatol (2010) 0.75
Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience. Int J Clin Exp Pathol (2014) 0.75
Management of hepatitis B virus infection after liver transplantation. World J Gastroenterol (2015) 0.75
Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation (2015) 0.75
Prophylactic managements of hepatitis B viral infection in liver transplantation. World J Gastroenterol (2016) 0.75
Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol (2016) 0.75
Safety of Complete and Sustained Prophylaxis Withdrawal in Patients Liver-transplanted for Hepatitis B Virus-related Cirrhosis at Low Risk of Hepatitis B Virus Recurrence. J Clin Exp Hepatol (2011) 0.75
Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therap Adv Gastroenterol (2013) 0.75
What is the optimal regimen for preventing hepatitis B recurrence after liver transplantation? Nat Clin Pract Gastroenterol Hepatol (2008) 0.75
Adult-to-adult right-lobe living donor liver transplantation in recipients with hepatitis B virus-related benign liver disease and high model end-stage liver disease scores. Surg Today (2013) 0.75
[4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009]. Wien Klin Wochenschr (2010) 0.75
Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet (2003) 4.49
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood (2004) 4.40
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology (2006) 2.30
Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. Hepatology (2004) 2.17
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05
The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology (2015) 2.04
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology (2012) 1.96
Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology (2002) 1.92
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology (2011) 1.89
Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.89
Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust (2003) 1.86
Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust (2003) 1.84
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2006) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology (2010) 1.56
Approaching the promise of operational tolerance in clinical transplantation. Transplantation (2011) 1.54
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology (2009) 1.54
The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest (2004) 1.53
Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl (2009) 1.50
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology (2002) 1.50
Management of healthcare workers after occupational exposure to hepatitis C virus. Med J Aust (2003) 1.49
Naïve CD8 T cell activation by liver bone marrow-derived cells leads to a "neglected" IL-2low Bimhigh phenotype, poor CTL function and cell death. J Hepatol (2012) 1.48
Hereditary lysozyme amyloidosis: spontaneous hepatic rupture (15 years apart) in mother and daughter. role of emergency liver transplantation. Liver Transpl (2006) 1.46
Usage and outcomes of deceased donor liver allografts with preprocurement injury from blunt trauma. Liver Transpl (2009) 1.45
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology (2009) 1.44
Liver transplantation: a small-volume unit experience. ANZ J Surg (2008) 1.39
Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol (2002) 1.34
The liver: a special case in transplantation tolerance. Semin Liver Dis (2007) 1.33
Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol (2003) 1.28
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology (2008) 1.27
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology (2005) 1.25
The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J (2010) 1.24
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology (2004) 1.24
Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation, and treatment. J Gastroenterol Hepatol (2013) 1.24
SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. J Biochem Biophys Methods (2003) 1.23
Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl (2003) 1.19
Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol Alcohol (2006) 1.19
Role of primary intrahepatic T-cell activation in the 'liver tolerance effect'. Immunol Cell Biol (2002) 1.16
Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol (2007) 1.16
Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol (2006) 1.11
Intrahepatic immunity: a tale of two sites? Trends Immunol (2005) 1.11
Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology (2008) 1.11
Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol (2003) 1.09
Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol (2006) 1.08
Liver fibrosis: a balance of ACEs? Clin Sci (Lond) (2007) 1.08
Gene expression profiling of alcoholic liver disease in the baboon (Papio hamadryas) and human liver. Am J Pathol (2003) 1.08
Muscle mass and mortality in chronic liver disease: the impact of testosterone. Liver Transpl (2014) 1.07
Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta (2004) 1.06
Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome. Liver Int (2013) 1.05
Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation. J Hepatol (2012) 1.05
Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells. Gastroenterology (2002) 1.05
Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl (2009) 1.05
Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol (2010) 1.05
Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol (2010) 1.04
Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations. Hepatol Int (2011) 1.04
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology (2009) 1.03
Fibroblast activation protein and chronic liver disease. Front Biosci (2008) 1.03
Assessing liver fibrosis with serum marker models. Clin Biochem Rev (2007) 1.02
The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol (2015) 1.02
Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol (2008) 1.01
Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology (2004) 1.01
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2011) 1.01
Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) (2009) 1.01
Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis (2003) 0.98
Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol (2006) 0.98
Spontaneous acceptance of mouse kidney allografts is associated with increased Foxp3 expression and differences in the B and T cell compartments. Transpl Immunol (2011) 0.98
Risk factors for liver transplantation waiting list mortality. J Gastroenterol Hepatol (2007) 0.98
Direct effects of alcohol on hepatic fibrinolytic balance: implications for alcoholic liver disease. J Hepatol (2008) 0.98
Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. Hepatology (2003) 0.97
Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. J Med Virol (2002) 0.97
Differential bidirectional transfer of indinavir in the isolated perfused human placenta. Antimicrob Agents Chemother (2005) 0.97
Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family. Biochemistry (2003) 0.97
Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl (2013) 0.97
Chylous ascites caused by portal vein thrombosis treated with octreotide. J Gastroenterol Hepatol (2003) 0.96
Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver. Hepatol Int (2008) 0.96
Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. Lab Invest (2013) 0.96
Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant (2006) 0.94
Early intrahepatic antigen-specific retention of naïve CD8+ T cells is predominantly ICAM-1/LFA-1 dependent in mice. Hepatology (2005) 0.94
Inflammation and repair in viral hepatitis C. Dig Dis Sci (2008) 0.94
A case of fulminant hepatic failure in pregnancy. Hepatology (2010) 0.94
GH treatment in adults with chronic liver disease: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab (2002) 0.93
The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem (2009) 0.93
An international comparison of the effect of policy shifts to organ donation following cardiocirculatory death (DCD) on donation rates after brain death (DBD) and transplantation rates. PLoS One (2013) 0.93
Screening for hemochromatosis. Clin Chim Acta (2002) 0.92
The inaccuracy of cystatin C and creatinine-based equations in predicting GFR in orthotopic liver transplant recipients. Nephrol Dial Transplant (2009) 0.92
Iron storage disease in Asia-Pacific populations: the importance of non-HFE mutations. J Gastroenterol Hepatol (2013) 0.92